Lipella Pharmaceuticalsの空売り状況は、投資家がLipella Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Lipella Pharmaceuticals (NASDAQ:LIPO) 株価情報, 空売り情報

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

Cantor Fitzgerald analyst Jonathan Ruykhaver reiterates SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Overweight and maintains $24 price target.

News

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on SentinelOne, Maintains $24 Price Target

Morgan Stanley analyst Devin McDermott maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Underweight and lowers the price target from $27 to $26.

Morgan Stanley Maintains Underweight on Murphy Oil, Lowers Price Target to $26

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) surged to $0.25, marking a <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge">3.11% gain</a> in the past 24 hours and a 7.94% gain over the last week. The price move followed a $40 million sell-off by major whales, the launch of Dogecoin and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) Bridge, and the SEC's delay in Dogecoin ETF approval.
According to Cryptopolitan, Dogecoin whales liquidated nearly $40 million in holdings, a sizeable move sparking caution. Whale Alert reported two large moves to an unknown wallet: one for 210 million DOGE and another for 50 million DOGE. The latest $40 million outflow adds to this recent pattern of sizable withdrawals.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto?<a href="http://coinbase-consumer.sjv.io/m5ALXy"> Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
Blockchain developer, Psy, has introduced a bridge that links Solana Network with Dogecoin. Unlike the traditional bridges that rely on third-party custodians or multisignature signs, the innovative approach validates Dogecoin's proof of work consensus, reducing the risk on Solana and from bridge hacks.
The bridge captures Dogecoin block headers, which contain critical blockchain data such as previous block hashes, timestamps, difficulty targets, and Merkle roots, and verifies them on Solana.&nbsp;
When DOGE tokens are sent to the bridge, they are locked on the Dogecoin network, and an equivalent amount of QDOGE tokens are minted on Solana. Redeeming DOGE involves burning QDOGE on Solana, and using Wormhole's secure cross-chain messaging to release the original DOGE back to the user's Dogecoin address.
Per FXLeaders, the U.S. Securities and Exchange Commission (SEC) has delayed its decision on Grayscale Investments&#8217; DOGE ETF filing from March 2025. The delay, part of a broader review of over 70 crypto ETF applications, including those tied to Solana and Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), has stirred frustration among participants.&nbsp;
The SEC maintains that the extended timeline is necessary to ensure compliance with Section 6(b)(5) of the Exchange Act, which aims to prevent fraud and market manipulation.
The next decision window for the DOGE ETF is set for June. The SEC has clarified that this stage represents an additional analysis phase rather than an indication of any final stance. According to Polymarket, the odds of the DOGE ETF being approved before the end of July have dropped to 15%, reflecting a drop of 7% in just one day. The long-term outlook remains more optimistic with 2025 approval odds standing at 63%.
Technically, Dogecoin has recently formed a bull pennant pattern on the hourly chart, according to analyst Ali Martinez. It has initiated an upward move similar to the broader market action seen in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) after finding support near $0.2220.&nbsp;
The rally pushed DOGE past the $0.2350 and $0.2420 resistance zones, peaking at $0.2542 before a minor correction. Key resistance now stands at $0.2550 and $0.2680. If DOGE breaks out above $0.2680, a rally could follow to $0.280. The next major target is the $0.30 level if the upward rally holds.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SOL

$XRP

DOGE

Dogecoin Charges Toward $0.30 Amid Solana Bridge Buzz, Grayscale's DOGE ETF Delayed

Barclays analyst Tom O'Malley maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Equal-Weight and raises the price target from $170 to $185.

Barclays Maintains Equal-Weight on Analog Devices, Raises Price Target to $185

Morgan Stanley analyst Joseph Moore maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Overweight and raises the price target from $93 to $100.

MKSI

Morgan Stanley Maintains Overweight on MKS, Raises Price Target to $100

Morgan Stanley analyst Stan Zlotsky maintains LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) with a Equal-Weight and raises the price target from $28 to $34.

RAMP

Morgan Stanley Maintains Equal-Weight on LiveRamp Holdings, Raises Price Target to $34

Trading Ideas

DOUG

Douglas Elliman Shares Halted On Circuit Breaker To The Upside, Stock Now Up 21%

Barclays analyst Adrienne Yih maintains Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) with a Underweight and raises the price target from $8 to $11.

GOOS

Barclays Maintains Underweight on Canada Goose Hldgs, Raises Price Target to $11

Morgan Stanley analyst Keith Weiss maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Overweight and raises the price target from $720 to $785.

INTU

Morgan Stanley Maintains Overweight on Intuit, Raises Price Target to $785

Morgan Stanley analyst Chris Snyder maintains Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) with a Equal-Weight and raises the price target from $38 to $40.

FAST

Morgan Stanley Maintains Equal-Weight on Fastenal, Raises Price Target to $40

JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) said it is enhancing its international presence from Boston Logan International Airport by adding two daily nonstop summer routes to Madrid and Edinburgh, expanding its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45579287/jetblue-expands-transatlantic-service-from-boston-with-new-flights-to-madrid-and-edinburgh-taking-" rel="noreferrer noopener">European network for the 2025 travel season</a>.
With the start of service to Madrid, JetBlue becomes the only U.S. airline offering nonstop service between Boston and Spain&#8217;s capital.&nbsp;
On Thursday, the company confirmed that these services will run through October 25, 2025, as part of the airline&#8217;s continued push to strengthen Boston as a key transatlantic hub.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45093263/jetblue-in-talks-with-united-airlines-over-possible-partnership-report" rel="noreferrer noopener">JetBlue In Talks With United Airlines Over Possible Partnership: Report</a>
The airline also resumed its seasonal connection between Boston and London-Gatwick as it broadens its reach across the Atlantic. These developments support JetBlue&#8217;s broader JetForward strategy, designed to scale its East Coast leisure travel offerings and solidify its footprint in competitive international markets.
Despite the expansion, JetBlue shares traded lower on Friday. The dip may reflect broader geopolitical uncertainty after President Donald Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114556968834547173" target="_blank" rel="noreferrer noopener">announced</a> on Truth Social that he is &#8220;recommending a straight 50% tariff on the European Union,&#8221; citing stalled trade negotiations.
The tariff threat introduces a potential headwind for U.S.-EU travel and business links, which could weigh on investor sentiment surrounding airline stocks.
For U.S. corporations with heavy exposure to Europe, particularly in tech, autos, agriculture and aviation, the economic consequences could be significant if the <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom">European Union responds in kind</a>.
Daniel Shurz, JetBlue&#8217;s senior vice president overseeing revenue and network planning, highlighted the company&#8217;s goal to make European destinations more accessible and affordable for New England travelers. He noted that adding Madrid and Edinburgh also boosts JetBlue&#8217;s connectivity to domestic, Latin American, and Caribbean markets.
Ed Freni, executive director of aviation at Massport, emphasized Madrid&#8217;s cultural appeal and praised JetBlue&#8217;s debut service to Spain&#8217;s capital as a significant milestone.
Martha J. Sheridan, president and CEO of Meet Boston, said the new routes promote cultural and economic exchange and are expected to drive increased tourism from Europe to Boston.
JetBlue will operate the new routes with its Airbus A321 aircraft, offering both its signature Mint premium class and its award-winning Core experience.
The airline promises high-speed internet access, seatback entertainment, and curated in-flight meals. To mark the launch, introductory round-trip fares from Boston start at $699 to Madrid and $649 to Edinburgh in Core, with limited-time Mint fares also available.
These latest additions join JetBlue&#8217;s existing service from Boston to Amsterdam, Dublin, London-Heathrow, London-Gatwick, and Paris. Due to growing demand, the airline is also extending JFK-Edinburgh and JFK-Dublin routes through late October.
Price Action: JBLU shares are trading lower by 1.42% to $4.86 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom" target="_blank" rel="noreferrer noopener">Trump Tariff Threat Hits Europe: Stocks Sink As 50% Duties Loom</a></li>
</ul>
Photo by Coby Wayne via Shutterstock

Equities

Markets

Movers

Media

General

JBLU

JetBlue Adds Transatlantic Routes From Boston, But Stock Slips - Here's Why

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Friday.
The Dow traded down 0.70% to 41,566.04 while the NASDAQ fell 1.12% to 18,713.37. The S&amp;P 500 also fell, dropping, 0.87% to 5,791.25.
Check This Out: <a href="https://www.benzinga.com/25/05/45586356/wall-streets-most-accurate-analysts-give-their-take-on-3-industrial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrial Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Real estate shares fell by just 0.1% on Friday.
In trading on Friday, information technology stocks dipped by 1.4%.
Top Headline
Shares of Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) dipped more than 11% on Friday after the company released its first-quarter results.
Workday reported quarterly earnings of $2.23 per share, which beat the analyst consensus estimate of $2.01 by 10.95%. Quarterly revenue came in at $2.24 billion, which beat the Street estimate of $2.22 billion.
Workday sees second-quarter revenue of $2.16 billion, versus the $2.34 billion analyst estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares shot up 155% to $1.07 after the company announced new data from its Phase 2 OVATION 2 Study of IMNN-001.</li>
<li>Shares of Powell Max Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) got a boost, surging 84% to $0.5956.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares were also up, gaining 52% to $0.2033 after the company announced a business alliance with M-NEXT holdings.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Golden Heaven Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares dropped 51% to $2.26.</li>
<li>Shares of Bicara Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) were down 42% to $9.06 after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.</li>
<li>NetClass Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) was down, falling 27% to $3.80.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $61.42 while gold traded up 1.5% at $3,344.90.
Silver traded up 0.1% to $33.250 on Friday, while copper rose 1% to $4.7245.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.1%, while Spain's IBEX 35 Index fell 1.5%. London's FTSE 100 dipped 0.85%, Germany's DAX 40 declined 1.6% and France's CAC 40 fell 1.9% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei gaining 0.47%, Hong Kong's Hang Seng Index rising 0.24%, China's Shanghai Composite Index falling 0.94% and India's BSE Sensex gaining 0.95%.
Economics
U.S. sales of new single-family homes climbed by 10.9% from the previous month to an annualized rate of 743,000 units.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

BCAX

BLMZ

GDHG

IMNN

NTCL

PMAX

WDAY

Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results

Keybanc analyst Jason Celino maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Overweight and lowers the price target from $335 to $325.

Keybanc Maintains Overweight on Workday, Lowers Price Target to $325

Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)<a href="https://www.benzinga.com/money/how-to-buy-ripple-xrp"> jumped above $2.45</a>, reclaiming a key psychological level. The rise follows news of the first U.S.-listed XRP futures ETF, a newly activated coin burn mechanism, and technical indicators that are aligning with the bullish shift in sentiment.
The rally follows a steady climb from $2.32. It is seeing a rising open interest and the launch of a euro-denominated stablecoin on the XRP Ledger, under the EU&#8217;s MiCA regulatory framework.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto?<a href="http://coinbase-consumer.sjv.io/m5ALXy"> Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
Volatility Shares introduced the XRPI fund on the NASDAQ, marking the first futures-based ETF for XRP in the U.S. According to CoinDesk, the fund will allocate 80% of its assets to XRP futures contracts, giving institutional investors regulated exposure without requiring custody of the underlying asset. Bloomberg Intelligence analyst, Eric Balchunas, described XRPI as a &#8220;market first,&#8221; positioning it as a less volatile alternative to leveraged crypto ETFs.
Per OKX Learn, Ripple Labs has started rolling out a coin burn mechanism aimed at steadily cutting down the total supply of XRP in circulation. It&#8217;s a deflationary move that could support long-term value, and with regulatory clouds starting to lift, it gives investors another reason to take the project seriously.
An overhang had long been Ripple&#8217;s legal battle with the U.S. Securities and Exchange Commission (SEC). Ripple Labs settled the case, agreeing to pay $50 million after the SEC returned $75 million in previously imposed fines. With the classification dispute resolved, institutional engagement has resumed. Standard Chartered has lifted its year-end forecast for XRP to $5.50, pointing to the recent ETF greenlight, easing regulatory overhang, and a fresh wave of interest in real-world asset tokenization.
XRP has cleared resistance around $2.42–$2.45, reclaiming its 20-day exponential moving average. The RSI has turned neutral-to-bullish, while a modest decline in exchange balances suggests accumulation by long-term holders.
Blockchain intelligence platform, CryptoRank, reports that approximately 60 million XRP moved between whale wallets over the past 72 hours. Futures open interest fell by nearly $930 million, hinting at some degree of profit-taking and risk-off repositioning following the ETF news.
Open interest has begun to rise again in recent sessions, implying new directional bets may be forming. The broader market backdrop remains supportive. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues to trade at nearly $111,000 after its recent breakout, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) holds above $2,690. Altcoins like XRP are riding this momentum. Traders remain wary of sharp retracements, particularly in risk-sensitive environments.
The current support zone between $2.30 and $2.35 will be critical in gauging follow-through. A successful hold could open the door for a move toward $2.60, with highs near $3.40 as the next major target. The spotlight on XRP has shifted from legal drama to capital inflows, on-chain innovation, and institutional validation.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Ripple Rebounds; Stablecoin Launch And Burn Strategy Add Tailwind

Morgan Stanley analyst Devin McDermott maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and raises the price target from $131 to $132.

Morgan Stanley Maintains Equal-Weight on EOG Resources, Raises Price Target to $132

JP Morgan analyst Brian Essex maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Overweight and raises the price target from $120 to $140.

OKTA

JP Morgan Maintains Overweight on Okta, Raises Price Target to $140

Keybanc analyst Alex Markgraff maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Overweight and raises the price target from $770 to $850.

Keybanc Maintains Overweight on Intuit, Raises Price Target to $850

JP Morgan analyst Brian Essex maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Overweight and raises the price target from $250 to $275.

JP Morgan Maintains Overweight on Zscaler, Raises Price Target to $275

Morgan Stanley analyst Devin McDermott maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $186 to $183.

FANG

Morgan Stanley Maintains Overweight on Diamondback Energy, Lowers Price Target to $183

JP Morgan analyst Mark Murphy maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Overweight and raises the price target from $660 to $770.

JP Morgan Maintains Overweight on Intuit, Raises Price Target to $770

Press Releases

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Health Care

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Peraso Inc. (NASDAQ: PRSO): A Critical Enabler Positioned for AI, 5G, and Telecom Growth – More Stock Pure-Plays inside….

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

Spartan Capital Securities, LLC Announces Key February Transactions

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

Comments

Lipella Pharmaceuticals

空売り

Lipella Pharmaceuticals (NASDAQ:LIPO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル